The acridone alkaloid acronycine first isolated from Acronychia baueri Schott (Rutaceae) in 1948, was later shown to exhibit a promising activity against a broad spectrum of solid tumors. Nevertheless, clinical trials only gave poor results, probably due to the moderate potency and low water solubility of this alkaloid. Early studies on structure-activity relationships in the series concluded that the 1,2-double bond was an essential structural requirement to observe cytotoxic activity. It is the reason why the isolation in our laboratory of the unstable acronycine epoxide from several New-Caledonian Sarcomelicope species led to the hypothesis of bioactivation of acronycine by transformation of the 1,2-double bond into the corresponding oxirane in vivo. Consequently, there was interest in the search for acronycine derivatives modified in the pyran ring and having improved stability, but a similar reactivity toward nucleophilic agents as acronycine epoxide. Accordingly, we synthesized a series of cis- and trans-1,2-dihydroxy-1,2-dihydroacronycine diesters which exhibited interesting antitumor properties with a broadened spectrum of activity and increased potency when compared with acronycine. (±)-Cis-1,2-diacetoxy-1,2-dihydroacronycine was of particular interest, due to its marked activity in vivo against the resistant solid tumor C 38 colon carcinoma. The demonstration that acronycine should interact with DNA by some noncovalent process able to stabilize the double helix against thermal denaturation prompted us to develop benzo[b]acronycine analogues possessing an additional aromatic ring linearly fused on the natural alkaloid basic skeleton. When tested against a panel of cancer cell lines in vitro, cis-1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine diesters exhibited cytotoxic activities within the same range of potency as the most active drugs currently used in cancer chemotherapy. In vivo, cis-1,2-diacetoxy-1,2-dihydrobenzo[b]acronycine (S23906-1), selected for further preclinical development, demonstated a marked antitumor activity in human orthotopic models of lung, ovarian and colon cancers xenografted in nude mice.